Boehringer Ingelheim is a research-driven biopharmaceutical company with the goal of improving the health and lives of humans and animals. Their focus is on diseases in areas with a high unmet medical need through developing innovative therapies that can improve and extend lives. In Animal Health, Boehringer Ingelheim is one of the world’s leading providers of vaccines, therapeutics and preventative care offerings that protect animals from disease and pain. Family-owned since its foundation in 1885, Boehringer Ingelheim is one of the top 20 companies in the pharmaceutical industry. Their aim is to transform the lives of patients – across generations. This goal inspires all of their over 53,000 employees who create value through innovation. In 2022, Boehringer Ingelheim achieved net sales of 24.1 billion euros.